Potential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects

In 2012, prostate cancer will once again be the second-leading cause of cancer death of American males. Although initially treatable, prostate cancer can recur in a hormone refractory form that is not responsive to current available therapies. The mortality rate associated with hormone refractory pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Shodeinde, Adetola L, Barton, Beverly E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400487/
https://www.ncbi.nlm.nih.gov/pubmed/22815644
http://dx.doi.org/10.2147/OTT.S32559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400487/
https://www.ncbi.nlm.nih.gov/pubmed/22815644
http://dx.doi.org/10.2147/OTT.S32559

Ejemplares similares